Katherine E. Wolski

3.4k total citations
20 papers, 1.7k citations indexed

About

Katherine E. Wolski is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Katherine E. Wolski has authored 20 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Cardiology and Cardiovascular Medicine, 7 papers in Surgery and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Katherine E. Wolski's work include Acute Myocardial Infarction Research (10 papers), Antiplatelet Therapy and Cardiovascular Diseases (6 papers) and Coronary Interventions and Diagnostics (5 papers). Katherine E. Wolski is often cited by papers focused on Acute Myocardial Infarction Research (10 papers), Antiplatelet Therapy and Cardiovascular Diseases (6 papers) and Coronary Interventions and Diagnostics (5 papers). Katherine E. Wolski collaborates with scholars based in United States, United Kingdom and Australia. Katherine E. Wolski's co-authors include Eric J. Topol, A. Michael Lincoff, Matthew J. Eagleton, Yuki Kuramochi, Tara M. Mastracci, Deepak L. Bhatt, Matthew R. Follansbee, Stephen G. Ellis, Steven P. Marso and Derek P. Chew and has published in prestigious journals such as The Lancet, Circulation and Annals of Internal Medicine.

In The Last Decade

Katherine E. Wolski

18 papers receiving 1.6k citations

Peers

Countries citing papers authored by Katherine E. Wolski

Since Specialization

Citations

This map shows the geographic impact of Katherine E. Wolski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Katherine E. Wolski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Katherine E. Wolski more than expected).

Fields of papers citing papers by Katherine E. Wolski

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Katherine E. Wolski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Katherine E. Wolski. The network helps show where Katherine E. Wolski may publish in the future.

Co-authorship network of co-authors of Katherine E. Wolski

This figure shows the co-authorship network connecting the top 25 collaborators of Katherine E. Wolski. A scholar is included among the top collaborators of Katherine E. Wolski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Katherine E. Wolski. Katherine E. Wolski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Cardiorenal risk of celecoxib compared with naproxen or ibuprofen in arthritis patients: insights from the PRECISION trial 2022 ·European Heart Journal - Cardiovascular Pharmacotherapy ·(unknown), Peter Libby, M. Elaine Husni, Qiuqing Wang, L Wiśniewski, Deborah Davey, Katherine E. Wolski, Feng Xia, Weihang Bao, Chris Walker, Frank Ruschitzka, Steven E. Nissen, Thomas F. Lüscher	22
2	Strengthening the interpretability of clinical trial results by assessing the effect of informative censoring on the primary estimand in PRECISION 2020 ·Clinical Trials ·Weihang Bao, Michael Gaffney, Milton L. Pressler, Rana Fayyad, Wayne Wisemandle, Bruce Beckerman, Katherine E. Wolski, Steven E. Nissen	0
3	Effect of Left Ventricular Conduction Delay on All-Cause and Cardiovascular Mortality (from the PRECISION Trial) 2019 ·The American Journal of Cardiology ·Erich L. Kiehl, Venu Menon, Kyle Mandsager, Katherine E. Wolski, L Wiśniewski, Steven E. Nissen, A. Michael Lincoff, Jeffrey Borer, Thomas F. Lüscher, Daniel J. Cantillon	6
4	Gastrointestinal Events in Arthritis Patients at Increased Cardiovascular Risk Treated Chronically with Celecoxib, Naproxen or Ibuprofen: The Precision Randomized Controlled Trial 2017 ·Gastroenterology ·Neville D. Yeomans, David Y. Graham, M. Elaine Husni, Daniel H. Solomon, Tyler Stevens, John J. Vargo, Qiuqing Wang, L Wiśniewski, Katherine E. Wolski, Steven E. Nissen	0
5	Differences in Safety of Nonsteroidal Antiinflammatory Drugs in Patients With Osteoarthritis and Patients With Rheumatoid Arthritis 2017 ·Arthritis & Rheumatology ·Daniel H. Solomon, M. Elaine Husni, Katherine E. Wolski, L Wiśniewski, Jeffrey Borer, David Y. Graham, Peter Libby, A. Michael Lincoff, Thomas F. Lüscher, Venu Menon, Neville D. Yeomans, Qiuqing Wang, Weihang Bao, Manuela Berger, Steven E. Nissen, (unknown)	39
6	Fenestrated and branched endovascular aneurysm repair outcomes for type II and III thoracoabdominal aortic aneurysms 2016 ·Journal of Vascular Surgery ·Matthew J. Eagleton, Matthew R. Follansbee, Katherine E. Wolski, Tara M. Mastracci, Yuki Kuramochi	219
7	Twelve-year results of fenestrated endografts for juxtarenal and group IV thoracoabdominal aneurysms 2015 ·Journal of Vascular Surgery ·Tara M. Mastracci, Matthew J. Eagleton, Yuki Kuramochi, (unknown), Katherine E. Wolski	186
8	Impact of alterations in target vessel curvature on branch durability after endovascular repair of thoracoabdominal aortic aneurysms 2015 ·Journal of Vascular Surgery ·(unknown), (unknown), Katherine E. Wolski, (unknown), (unknown), Yuki Kuramochi, Matthew J. Eagleton	19
9	β-Blockers and Progression of Coronary Atherosclerosis: Pooled Analysis of 4 Intravascular Ultrasonography Trials 2007 ·Annals of Internal Medicine ·İlke Sipahi, E. Murat Tuzcu, Katherine E. Wolski, Stephen J. Nicholls, Paul Schoenhagen, Bo Hu, Craig Balog, Mehdi H. Shishehbor, William A. Magyar, Timothy D. Crowe, Samir Kapadia, Steven E. Nissen	67
10	Effects of Normal, Pre-Hypertensive, and Hypertensive Blood Pressure Levels on Progression of Coronary Atherosclerosis 2006 ·Journal of the American College of Cardiology ·İlke Sipahi, E. Murat Tuzcu, Paul Schoenhagen, Katherine E. Wolski, Stephen J. Nicholls, Craig Balog, Timothy D. Crowe, Steven E. Nissen	131
11	Ischemic and bleeding outcomes in women treated with bivalirudin during percutaneous coronary intervention: A subgroup analysis of the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE)–2 trial 2006 ·American Heart Journal ·Matthews Chacko, A. Michael Lincoff, Katherine E. Wolski, David J. Cohen, John A. Bittl, Alexandra J. Lansky, Yoshihiro Tsuchiya, Amadeo Betriu, Michael H. Yen, Derek P. Chew, Leslie Cho, Eric J. Topol	34
12	Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial) 2005 ·The American Journal of Cardiology ·Derek P. Chew, A. Michael Lincoff, Hitinder S. Gurm, Katherine E. Wolski, David J. Cohen, Tim Henry, Frederick Feit, Eric J. Topol	72
13	ST-segment resolution 60 minutes after combination treatment of abciximab with reteplase or reteplase alone for acute myocardial infarction (30-day mortality results from the resolution of ST-segment after reperfusion therapy substudy) 2004 ·The American Journal of Cardiology ·Fernando Cura, Marco Roffi, (unknown), Katherine E. Wolski, A. Michael Lincoff, Eric J. Topol, Michael S. Lauer	19
14	Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: Results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET) 2002 ·American Heart Journal ·A. Michael Lincoff, Neal S. Kleiman, (unknown), (unknown), Kelly Maresh, Katherine E. Wolski, Eric J. Topol	128
15	Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study 2001 ·The Lancet ·Herbert D. Aronow, Eric J. Topol, Matthew T. Roe, Penny L. Houghtaling, Katherine E. Wolski, A. Michael Lincoff, Robert A. Harrington, Robert M. Califf, E. Magnus Ohman, Neal S. Kleiman, Mátyás Keltai, Robert G. Wilcox, Alec Vahanian, Paul W. Armstrong, Michael S. Lauer	236
16	Defining the Optimal Activated Clotting Time During Percutaneous Coronary Intervention 2001 ·Circulation ·Derek P. Chew, Deepak L. Bhatt, A. Michael Lincoff, David J. Moliterno, Sorin J. Brener, Katherine E. Wolski, Eric J. Topol	171
17	Abciximab reduces mortality in diabetics following percutaneous coronary intervention 2000 ·Journal of the American College of Cardiology ·Deepak L. Bhatt, Steven P. Marso, A. Michael Lincoff, Katherine E. Wolski, Stephen G. Ellis, Eric J. Topol	234
18	The benefit of abciximab in percutaneous coronary revascularization is not device-specific 2000 ·The American Journal of Cardiology ·Deepak L. Bhatt, A. Michael Lincoff, Robert M. Califf, Maarten L. Simoons, James E. Tcheng, Sorin J. Brener, Katherine E. Wolski, Eric J. Topol	19
19	Pronounced Benefit of Coronary Stenting and Adjunctive Platelet Glycoprotein IIb/IIIa Inhibition in Complex Atherosclerotic Lesions 2000 ·Circulation ·Fernando Cura, Deepak L. Bhatt, A. Michael Lincoff, Samir Kapadia, Philippe L. L’Allier, Khaled M. Ziada, Katherine E. Wolski, David J. Moliterno, Sorin J. Brener, Stephen G. Ellis, Eric J. Topol	59
20	Effect of abciximab on the pattern of reperfusion in patients with acute myocardial infarction treated with primary angioplasty 1999 ·The American Journal of Cardiology ·Sorin J. Brener, Lawrence A. Barr, J.E.B. Burchenal, Katherine E. Wolski, Mark B. Effron, Eric J. Topol	23

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact